A Universal Biomarker
for cancer
Travera is using a breakthrough technology to measure which cancer drugs work against each individual’s unique cancer cells. We are developing a universal biomarker for enabling oncologists to quickly determine which drugs to prescribe based on the actual responses of their patients’ tumor cells to candidate drugs.
About Us
Travera was founded in 2017 to commercialize a breakthrough measurement technology and biomarker developed in the Manalis Laboratory in the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT).
What’s New at Travera
Travera raises $5.5M Series A Extension led by Khosla Ventures
MEDFORD, MASSACHUSETTS – July 15, 2021 – Travera, Inc. has announced that it has recently closed a $5.5 million Series A Extension. The financing was led by Khosla Ventures and joined by existing investor Horizons Ventures and a new investor in the company, MSA...
Travera expands testing lab with move to Medford, Massachusetts
MEDFORD, MASSACHUSETTS – January 4, 2021 – Travera, LLC has announced that it has moved from its 1,000 sq.ft. laboratory in Cambridge, Massachusetts to a 3,500 sq.ft. lab in Medford, Massachusetts. This new location remains near the Massachusetts Institute of...
Travera Awarded Competitive Grant from the National Science Foundation
CAMBRIDGE, MASSACHUSETTS - OCTOBER 8, 2020 – Travera, LLC has been awarded a National Science Foundation (NSF) Phase II Small Business Innovation Research (SBIR) grant in the amount of $1 million to conduct research and development (R&D) of the company's suspended...
Read our white paper
Travera’s solution is to try drugs on the OUTSIDE of the patient rather than INSIDE. That is, remove some of the cancer cells from the patient and apply the drugs to these removed (“ex vivo”) cancer cells. We can then try many different cancer drugs (in very small quantities) against these cancer cells. This approach completely eliminates toxicity, dramatically reduces the cost (because we only need enough drug to treat a few cells, not a whole person), and only takes a couple of days.
.
Click here to download the white paper
Patient Testimonial
“While the introduction of several novel agents and regimens for newly diagnosed multiple myeloma and relapsed/refractory multiple myeloma has improved outcomes, it has also increased the complexity of treatment selection since not all patients respond. Having a test that can prospectively assess an individual’s personalized response is a much needed breakthrough for patients with multiple myeloma.”
Jack Aiello
Patient advocate and multiple myeloma survivor
